MedTrace Logo

Functional MRI in Predicting Response to Chemotherapy

NCT03969524 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-12-29

No results posted yet for this study

Summary

• Address the accuracy of functional MRI techniques to predict response to neoadjuvant chemotherapy given to local advanced breast cancer patients with correlation with pathology thus allowing early chemotherapy regimen modification to increase number of patients achieving pathological complete response or save patients from toxic effects of ineffective chemotherapy.

Conditions

  • Breast Cancer Patients

Interventions

DEVICE

MRI

Patients will undergo magnetic resonance imaging (MRI) at baseline (T0) (before NAC) and after the 2nd cycle of neoadjuvant chemotherapy(T2). Histopathological examination (gold standard) of the surgical specimen will be done for each patient and Compared to the results of MRI.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Osama HA El-Sayed, Professor · Assiut University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-15
Primary Completion
2023-06-15
Completion
2023-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03969524 on ClinicalTrials.gov